TIL Instil Bio, Inc.

Instil Bio, Inc is a global, clinical-stage cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of cancer. We are building on the decades-long foundation of TIL efficacy in treating solid tumors, applying our cell therapy experience and TIL manufacturing platform to bring the promise of TIL therapy to patients in need. Instil Bio has research and cell therapy manufacturing facilities in Los Angeles, CA and Manchester, UK, with corporate offices in Dallas, TX.

$19.50  +0.10 (0.52%)
As of 07/23/2021 15:58:37 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/19/2021
Outstanding shares:  128,743,123
Average volume:  393,839
Market cap:   $2,497,616,586
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45783C101
ISIN:        US45783C1018
Sedol:      BLFF921
Valuation   (See tab for details)
PE ratio:   -611.46
PB ratio:   3.76
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy